drugset

drugset / Trial / NCT03801668

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

NCT03801668 ↗

Phase 3 Unknown 294 enrolled Huazhong University of Science and Technology CSPC Ouyi Pharmaceutical Co., Ltd. · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

It is a trial to compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus S-1 (SOX) as first-line treatment in advanced or recurrent gastric adenocarcinoma.

Timeline

Start: 2019-03-08
Primary completion: 2022-12-31
Completion: 2023-03-31

Publications

Dai YH, Yu XJ, Xu HT, Zhuang L, Zhang MS, Zou YM, Fu Q, Qiu H, Yuan XL. Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study). Ther Adv Med Oncol. 2022 Aug 12;14:17588359221118020. doi: 10.1177/17588359221118020. eCollection 2022.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Oxaliplatin	Small molecule	130 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	260 mg/m2	—
Comparator	S-1	Small molecule	80 mg/m2	Oral

Indications